JNJ-18038683

JNJ-18038683 is a drug that was developed by Johnson & Johnson for the potential treatment of cognitive disorders, insomnia, and depression. It acts as a selective 5-HT2A receptor antagonist and 5-HT2C receptor inverse agonist, and has been shown to enhance cognition in animal studies.

Pharmacology

JNJ-18038683 is a serotonin antagonist and inverse agonist at the 5-HT2A and 5-HT2C receptors. These receptors are part of the serotonin system, which plays a key role in regulating mood, cognition, and sleep. By blocking the activity of these receptors, JNJ-18038683 may help to improve symptoms in conditions such as cognitive disorders, insomnia, and depression.

Clinical trials

JNJ-18038683 has undergone Phase I clinical trials for the treatment of cognitive disorders, insomnia, and depression. However, the results of these trials have not been publicly disclosed, and it is unclear whether the drug will proceed to Phase II clinical trials.

See also

• 5-HT2A receptor
• 5-HT2C receptor
• Serotonin antagonist
• Inverse agonist
• Cognitive disorders
• Insomnia
• Depression

References

JNJ-18038683 Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski